35 results
10-K
2023 FY
EX-10.12
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
, at [***] sole cost and expense, in connection with its activities set forth in this Section 11.6, including by being joined as a party plaintiff
424B5
AUTL
Autolus Therapeutics plc
9 Feb 24
Prospectus supplement for primary offering
5:15pm
the right itself. The complaint must:
state that the plaintiff was a stockholder at the time of the transaction of which the plaintiff complains … or that the plaintiff’s shares thereafter devolved on the plaintiff by operation of law; and
allege with particularity the efforts made by the plaintiff
8-K
EX-1.1
AUTL
Autolus Therapeutics plc
8 Feb 24
Autolus Announces Pricing of Underwritten Offering
4:17pm
or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party against any loss, claim, damage, liability or expense
8-K
EX-10.1
AUTL
Autolus Therapeutics plc
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect of such claim or litigation, (ii) does
8-K
EX-10.2
AUTL
Autolus Therapeutics plc
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect
S-3ASR
3p82e5hz9 f8pxn0gn
7 Feb 24
Automatic shelf registration
10:00pm
6-K
EX-1.1
6ewlwtmv630tp7hbft
9 Dec 22
Autolus Announces Pricing of Public Offering
5:43pm
424B5
t505bwxak
9 Dec 22
Prospectus supplement for primary offering
5:40pm
424B5
90topide 77n
8 Dec 22
Prospectus supplement for primary offering
4:10pm
6-K
EX-99.1
jx9n4n4sfti5ge9q1tp
8 Nov 21
Securities Purchase Agreement
5:28pm
6-K
EX-99.2
vfzhw8b g2yvi
8 Nov 21
Securities Purchase Agreement
5:28pm
424B5
q0zrvajmxrqb27sp
19 Aug 21
Prospectus supplement for primary offering
4:13pm
F-3
axthz8x qpvr46c
6 Aug 21
Shelf registration (foreign)
2:30pm
424B5
30qihd93hxx
11 Feb 21
Prospectus supplement for primary offering
5:16pm
424B5
3r2j1qn8
8 Feb 21
Prospectus supplement for primary offering
5:27pm
424B5
ykos45dd9yjwmd
18 Sep 20
Prospectus supplement for primary offering
8:01am
6-K
EX-1.1
krfmag0el1rq
18 Sep 20
Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ESMO
7:12am